New drug combo aims to outperform immunotherapy in Hard-to-Treat stomach cancer

NCT ID NCT07716449

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether an experimental drug called QLS31905, combined with chemotherapy (CAPOX), works better than the current immunotherapy drug sintilimab plus the same chemotherapy for people with advanced gastric or gastroesophageal junction cancer. The study includes patients whose tumors have a specific protein (CLDN18.2) and low PD-L1 levels, a group that often does not benefit from standard immunotherapy. Researchers will measure how long participants live without their cancer worsening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of an experimental drug called QLS31905 and chemotherapy (CAPOX: capecitabine and oxaliplatin)
What this could lead to
If successful, this could provide a new first-line treatment option for people with a specific type of advanced gastric cancer that does not respond well to current immunotherapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The experimental combination may not prove more effective or safer than the existing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.